Small cell lung carcinoma with KIF5B-RET fusion partially responded to the 4th-line therapy with anlotinib: A case report

Figure 1 Chest computed tomography and histological evaluation. A-C: The baseline chest computed tomography assessment in May 2021 included evaluation of lung lesions, lymph node lesions, and pleural lesions; D-F: Hematoxylin and eosin staining with magnifications of 100 x, 200 x, and 400 x revealed extensive-stage disease small cell lung cancer (SCLC) classification; G-L: Immunohistochemical staining displayed cytokeratin CAM5.2, CD56, Ki67, synaptophysin, chromogranin A, and thyroid transcription factor-1 in the SCLC tumor biopsy.

Figure 2 Imaging evaluations and serum tumor biomarker testing during treatment. A-G: Imaging assessments of the tumor were conducted during the 1st to 4^th line chemotherapy, yellow arrows were used to indicate primary tumors and metastatic lesions; H: Serum levels of progastrin-releasing peptide, neuron-specific enolase, and carbohydrate antigen 125 were measured to monitor clinical responses. NSE: Neuron-specific enolase; CA125: Carbohydrate antigen 125; ProGRP: Progastrin-releasing peptide.